Letter to the Editor

Erythrodermic psoriasis de novo versus skin lesions in chronic lymphocytic leukaemia

Anna Słomiak-Wąsik1, Magdalena Jałowska1, Katarzyna Iwanik2, Ryszard Żaba1, Zygmunt Adamski1

1Department of Dermatology and Venereology, Poznan University of Medical Sciences, Poznan, Poland
2Department of Clinical Pathology, Poznan University of Medical Sciences, Poznan, Poland

Adv Dermatol Allergol 2020; XXXVII (2): 277–279
DOI: https://doi.org/10.5114/ada.2020.94849

Erythroderma is an inflammatory skin disease that affects over 90% of the body surface. It is usually associated with skin desquamation and pruritus [1]. This rare and severe form affects 1–2.25% of patients diagnosed with psoriasis [2]. Differential diagnosis for erythroderma includes inter alia dandruff, atopic dermatitis, drug eruption, seborrheic dermatitis, erythrodermic stage of cutaneous lymphoma or even skin manifestation of leukaemia, including chronic lymphocytic leukaemia (CLL) [2, 3]. Only 25% of erythroderma cases are caused by the psoriasis [4].

Skin lesions are present in 5–25% of CLL patients [5]. The most common type is a lump or wart associated with limited lymphocyte B skin infiltration. Exfoliative dermatitis, also manifested as erythroderma have been reported in CLL [6].

Skin lesions associated with CLL might develop primarily as a skin leukaemia (manifested as blisters, ulcerations, eczema and gingival overgrowth) or secondary to hematologic or autoimmune diseases associated with CLL (e.g. skin neoplasm, petechia, exfoliative dermatitis, erythroderma or pemphigoid) [7, 8].

A 56-year-old man diagnosed with psoriasis vulgaris was referred to our department due to scaly lesions on the elbows. The patient had a 1-year history of progressively deteriorating skin lesions, but no previous medical files were available for review. No co-morbidities, oral medication intake and significant family history was reported by the patient. Previous treatment of psoriatic skin lesions included topical prescription ointment, though no information regarding ointment composition were available. Also no general symptoms such as weight loss or fever were noted. At admission erythroderma associated with itch (without desquamation) and mild ankle oedema was reported (Figure 1). Apart from that, numerous, swollen, painless lymph nodes were noted in the following locations: right lateral cervical triangle, bilateral supraclavicular area, and bilateral axillary area. The lymph node in the right lateral cervical triangle was modelling shape of the neck, what was noted by the patient 1 year ago. Due to no associated pain the patient decided not to report this finding to his general physician, also no lymph node physical examination was carried out in the preceding year.

An elevated lymphocyte count (7.01 × 10³/μl, cutoff level: 4.50 × 10³/μl) and white blood cell count (12.48 × 10³/μl, cutoff level: 11.00 × 10³/μl) were found. Other de-

![Figure 1. Dermatological status at admission – erythroderma](image-url)
TNF inhibitors are used successfully to treat psoriasis, α of TNF-α to psoriasis and CLL. We suspect that common interactions of TNF-α as a proinflammatory cytokine is involved in pathophysiology of both psoriasis and CLL. Various responses of leukemic cells to TNF-α stimulation were discovered by the scientists [9]. In CLL patients TNF-α elevation is observed in blood serum [9–11]. It is suspected that TNF-α is involved in CLL progression. What is more, TNF-α as a proinflammatory cytokine is involved in pathophysiology of both psoriasis and CLL. We suspect that common interactions of TNF-α contributed to CLL development in our patient. TNF inhibitors are used successfully to treat psoriasis, 5 types of the drug are available in Poland [6]. First trials of TNF inhibitors in CLL are available. Balato et al. reported a case of a 41-year-old female diagnosed with psoriasis and CLL treated initially with etanercept [12]. After change to infliximab, both PSI index improved as well as CLL progression was stopped. After 18 months of such treatment, remission of psoriasis was still observed as well as no lymphocyte elevation was noted. Infliximab treatment is one of the available therapeutic options for our patients after approval by the haematologist. Anyway, it is worth noticing that biological treatment is contraindicated in patients with a history of malignant neoplasm in the last 5 years.

Uncertain past medical history, lack of medical files, negative family history and lack of common psoriatic skin lesions at admission encouraged authors to perform skin biopsy in order to confirm diagnosis. Additional doubts regarding condition underlying erythroderma resulted from suspicion and confirmation of CLL in the patient. Authors highlight the significance of skin biopsy examination in erythroderma origin disclosure since psoriasis underlies only one fourth of cases. Thorough physical examination and basic laboratory tests remain crucial for establishing diagnosis. Management of CLL Rai stage I includes regular follow-up by the haematologist and treatment introduction when progression occurs.

Conflict of interest

The authors declare no conflict of interest.

References

1. Okoduwa C, Lambert WC, Schwartz RA, et al. Erythroderma: review of a potentially life-threatening dermatosis. Indian J Dermatol 2009; 54: 1-6.
2. Stinco G, Errichetti E. Erythodermic psoriasis: current and future role of biologicals. BioDrugs 2015; 29: 91-101.
3. Rym BM, Mourad M, Bechir Z, et al. Erythroderma in adults: a report of 80 cases. Int J Dermatol 2005; 44: 731-35.
4. Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62: 655-62.
5. Robak E, Robak T. Skin lesions in chronic lymphocytic leukaemia. Leuk Lymphoma 2007; 48: 855-65.
6. Dhir R. Chronic lymphocytic leukaemia manifestating as exfoliative dermatitis. Indian J Dermatol Venereol Leprol 1995; 61: 102-3.
7. Lu C, Li L, Qiao Q, et al. Cutaneous manifestations in a patient with chronic lymphocytic leukaemia involving the head, neck and distal extremities. Exp Ther Med 2015; 9: 877-79.
8. Agnew KL, Ruchlemer R, Catovsky D, et al. Cutaneous findings in chronic lymphocytic leukaemia. Br J Dermatol 2004; 150: 1129-35.
9. Wąsik-Szczepanek E. Czynniki martwicy guza i jego rola w przewlekłej białaczce [mofocytowej (PBL) [Tumor necrosis factor and its role in chronic lymphocytic leukaemia]. Acta Haematol Pol 2012; 43: 146-9.
10. Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical significance of tumor necrosis factor-alpha plasma level in...
patients having chronic lymphocytic leukemia. Blood 2002; 100: 1215-9.
11. Bojarska-Junak A, Hus I, Wasik Szczepanek E, et al. Periph-
eral blood and bone marrow TNF and TNF receptors in early
and advanced stages of B-CLL in correlation with ZAP-70
protein and CD38 antigen. Leuk Res 2008; 32: 225-33.
12. Balato A, Lembo S, Cirillo T, et al. Anti-tumor necrosis factor-
alpha therapy in the management of psoriasis and B-chronic
lymphocytic leukemia. Case Rep Dermatol 2011; 3: 60-3.